For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Attruby represents a genuine change. These groundbreaking therapies protect the transthyretin protein, slowing its damaging build-up and reducing the severity of the disease . Individuals are now reporting improvemen… Read More